While 20 states originally filed the lawsuit in December, an amended complaint filed March 1 now lists 40 states as plaintiffs in the suit, according to the report.
The lawsuit alleges six drugmakers — Heritage Pharmaceuticals, Mylan, Teva Pharmaceutical Industries, Mayne Pharma, Aurobindo Pharma and Citron Pharma —colluded to set fixed prices of two common drugs and split up market share.
The drugs involved are a delayed-release version of the antibiotic doxycycline hyclate and the diabetes medication glyburide. In October 2013, doxycycline cost $20 for 500 tablets. In May 2014, that price jumped to $1,849.
The lawsuit claims Heritage conspired with Teva, Aurobindo and Citron to raise prices for glyburide and worked with Mylan and Maine to allocate and divide the market for doxycycline, according to the report.
While Heritage declined The New York Times’ request to comment on the original lawsuit, spokespeople for Teva and Mylan both said there was no evidence to suggest the drugmakers participated in any wrongdoings.
More articles on supply chain:
10 drugmakers with highest direct-to-consumer ad spending in 2016
The ‘price hikes fuel innovation’ argument is invalid, researchers say
FDA lifts pause on Seattle Genetics’ drug trials
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
